Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06650761
PHASE1

A Phase I Study of CDX-622

Sponsor: Celldex Therapeutics

View on ClinicalTrials.gov

Summary

This is a study to determine the safety of CDX-622 in healthy participants.

Official title: A Randomized, Double-Blind, Placebo-Controlled, Three-Part, Phase 1a Dose Escalation Clinical Trial to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-622 in Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

85

Start Date

2024-11-01

Completion Date

2026-04

Last Updated

2026-02-23

Healthy Volunteers

Yes

Interventions

DRUG

CDX-622

Up to 4 infusions of one of seven dosages of CDX-622 or up to 1 dose by subcutaneous injection of one of three dosages of CDX-622

DRUG

Normal Saline

Up to 4 infusions or 6 SC injections of normal saline

Locations (1)

Celerion, Inc.

Tempe, Arizona, United States